About Neuropacs
Neuropacs is a healthcare AI company that develops an AI-based imaging software suite designed to detect, analyze, and measure changes associated with neurodegenerative diseases. Their platform offers imaging analysis tools and proprietary algorithms that are compatible with existing imaging workflows. This technology enables clinicians and clinical researchers to support diagnosis and evaluate disease progression in both research and clinical settings.
Specifically for physicians, Neuropacs provides automated MRI processing and machine learning software to assist in diagnosing and differentiating common neurodegenerative forms of parkinsonism, including Parkinson’s disease (PD), multiple system atrophy parkinsonian variant (MSA), and progressive supranuclear palsy (PSP). The software utilizes a free-water imaging model to assess for neurodegeneration and a machine learning algorithm to analyze brain scans, providing clinicians with results indicating the likely presence of PD, MSA, or PSP. The test relies on a single, non-invasive diffusion MRI scan without radiotracers, and can be performed on 3 Tesla scanners from major vendors (Siemens, GE Healthcare, and Philips). The FDA has granted De Novo classification to Neuropacs, establishing a new regulatory category for a “Parkinsonian syndrome diagnostic aid,” making it the first device cleared under this classification. This software is intended to provide supplemental information for neuroradiologists and neurologists as part of a broader clinical assessment, particularly when differentiating these conditions from Parkinson’s disease is challenging.
Focus Areas
Business Intelligence
| Key Investors | Neuro Investment Group, LLC, HHS |
| Partnerships | Parkinson Study Group (for clinical trials), University of Florida, Mayo Clinic, Vanderbilt University (for research collaborations) |
| Technology | Cloud-based analysis platform, free-water imaging model, machine learning algorithm, compatible with standard diffusion MRI sequences on 3T MRI systems |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
Neuropacs offers physicians a crucial tool for more accurate and earlier differentiation of Parkinson's disease from atypical parkinsonism (MSAp and PSP), which are often challenging to distinguish clinically, especially in early stages. This can lead to more informed treatment planning and potentially revolutionize the standard of care for diagnosing parkinsonism. The system provides objective, imaging-derived information as a supplemental aid, and results should always be interpreted in conjunction with a comprehensive clinical evaluation and other diagnostic testing. The non-invasive nature of the diffusion MRI scan and its compatibility with standard 3T MRI systems from major vendors (Siemens, GE Healthcare, Philips) ensures ease of integration into existing workflows.
The Neuropacs software is designed for cloud-based analysis and integrates with existing MRI workflows, operating with standard diffusion MRI sequences on 3 Tesla clinical MRI systems from Siemens, GE Healthcare, and Philips. It is powered by AWS, ensuring scalability and high availability.
Reviews & Opinions
Videos
News, demos, and interviews about Neuropacs.
Videos load interactively. If none appear, search YouTube for Neuropacs →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Neuropacs.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]